Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy , Blood Cancer Discov, BCD(22): 2022,0074
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, MartÃnez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma , N Engl J Med, 387(6): 2022,495-505
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy , Nat Med, 28(4): 2022,713-723
Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen X CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma MajesTEC-1: a multicentre, open-label, single-arm, phase 1 study , Lancet, 398(10301): 2021,665-674
Garfall A, Cohen A, Stadtmauer E, Susanibar-Adaniya S, Vogl D, Waxman A Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy , Journal of Clinical Oncology, 40(1): 2021,106-107
Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M, Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melehorst J T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma , Blood Adv
, 3(19): 2019 ,2812-2815
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. , J Clin Invest
, 129(6): 2019,2210-2221
Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D. Prospective Study of Cardiac Evens During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. , J Clin Oncol., 37(22): 2019,1946-1955
Waxman Adam J, Clasen Suparna, Hwang Wei-Ting, Garfall Alfred, Vogl Dan T, Carver Joseph, O'Quinn Rupal, Cohen Adam D, Stadtmauer Edward A, Ky Bonnie, Weiss Brendan M Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. , JAMA Oncol, 4(3): 2018,e174519
Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr N D S, Bagg A, Levine BL, June CH, Stadtmauer EA Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. , The New England Journal of Medicine, 373(11): 2015,1040-7
